Johnson & Johnson

Johnson & Johnson (JNJ) remains near the bottom of its 52-week range, with the stock trading around $174 after a year that saw a high of $278.43. The healthcare giant carries a P/E of 30.66 on trailing EPS of $8.62. Revenue rose 8.1% year over year, but EPS fell 7.8%, squeezing net margin to 21.5% from a higher base a year ago. The Alpha Score of 40.2 reflects a neutral overall setup: quality scores a solid 59.3, value sits at 47.8, while momentum and sentiment are null, indicating no clear directional catalyst from those factors. The divergence between top-line growth and bottom-line contraction suggests cost pressures or one-time charges are weighing on profitability. Investors will watch for the next quarterly report, due in mid-July, for signs of margin stabilization or guidance updates that could break the stock out of its narrow trading band near the 52-week floor.

Johnson & Johnson shares trade near $170, hugging the lower end of a 52-week range that stretches from $174 to $278. At 30.7 times trailing earnings, the stock commands a premium reflective of its 21.5% net margin — among the widest in large-cap pharma. Revenue grew 8.1% year over year, but earnings per share slipped 7.8%, a divergence that weighs on the value score of 47.8. The Alpha Score of 52.8 leans on momentum strength (67.3) and quality (59.3), yet sentiment data remains absent, leaving the direction of factor support incomplete. Watch for the second-quarter earnings call later this month, where management will need to reconcile revenue acceleration with the profit drag to sustain the current multiple.

Johnson & Johnson trades near the midpoint of its 52-week range of $173.33 to $276.47. Revenue grew 8.1% year over year, but EPS fell 7.8%, reflecting higher costs or one-time charges. Net margin remains healthy at 21.5%. The company carries an Alpha Score of 47.4, with quality scoring highest at 59.3 and value at 48.2, while momentum registers null. The P/E of 29.93 is above the broader market, suggesting limited room for multiple expansion without stronger earnings. Investors will watch the next quarterly report for signs that revenue growth is translating back into profit growth, and whether the quality score can sustain its lead within the Alpha framework.

Johnson & Johnson shares sit near the top of their 52-week range ($173.33-$276.47), supported by 8.1% revenue growth and a 21.5% net margin. The P/E of 29.93 reflects the premium the market assigns to the healthcare giant's quality profile, which scores 59.3 on the Alpha Scale. But EPS growth slipped 7.8% year over year, dragging the value sub-score to 48.2 and the overall Alpha Score to 47.4. Momentum is null, suggesting the stock lacks near-term price catalysts. The next quarterly report will test whether revenue growth can offset margin pressure and stabilize earnings.

Johnson & Johnson (JNJ) sits near the top of its 52-week range at $276.47, with shares up sharply from the $173.33 low. The stock carries a P/E of 29.93, a premium that looks less rich against a 21.5% net margin but harder to justify with EPS down 7.8% year over year. Revenue grew 8.1%, so the earnings decline is cost-driven, not demand-driven. The Alpha Score of 47.4 reflects a neutral momentum read, with value at 48.2 and quality at 59.3; sentiment sits at 50. The gap between the quality score and the overall number suggests the market is paying for the franchise, not the current quarter. Watch the next earnings call for margin guidance, since the 8.1% top-line growth has yet to translate into profit growth. A narrower P/E would follow if the company holds costs in check.